3017909
print

Preeclampsia Risk Assessment (sFlt-1/PlGF Ratio)

PERA S/P
Example Reports
Abnormal
Normal

Ordering Recommendation

This test is to be used in conjunction with other laboratory tests and clinical assessments to aid in the risk assessment of pregnant women (singleton pregnancies between gestational age 23+0 to 34+6/7 weeks) hospitalized for hypertensive disorders of pregnancy (preeclampsia, chronic hypertension with or without superimposed preeclampsia, or gestational hypertension) for progression to preeclampsia with severe features (as defined by American College of Obstetricians and Gynecologists guidelines) within 2 weeks of being tested. 

New York DOH Approval Status

This test is New York state approved.

Specimen Required

Patient Preparation
Collect

Serum separator tube (SST), plain red, or pink (K2EDTA)

Specimen Preparation

Allow serum to clot completely at room temperature. Transfer 2 mL serum or plasma (Min: 0.5 mL) to an ARUP standard transport tube.

Storage/Transport Temperature

Preferred transport temp: Refrigerated. Also acceptable: Frozen.

Unacceptable Conditions

Grossly hemolyzed, lipemic, and/or icteric specimens

Remarks
Stability

Room Temperature: 24 hours; Refrigerated: 1 month; Frozen: 1 month

Methodology

Quantitative Immunofluorescence

Performed

Sun-Sat

Reported

1-3 days

Reference Interval

A sFlt-1/PlGF ratio greater than or equal to 40 is consistent with high risk for progression to preeclampsia with severe features within 2 weeks of presentation.
Test Number
 Components
 Reference Interval
  Preeclampsia sFlt-1/PlGF Ratio, S/P
<40

Interpretive Data

The sFlt-1/PlGF ratio is indicated to be used as an aid in the management of the patient and is a prognostic assay intended to stratify hospitalized patients into two risk groups (low risk and high risk of progression to preeclampsia with severe features within two weeks from presentation).

The clinical cutoff for the sFlt-1/PlGF ratio is 40.

If the result of the ratio is greater than or equal to 40, the pregnant woman would be at high risk for progression to preeclampsia with severe features within 2 weeks.

If the result of the ratio is less than 40, the pregnant woman would be at low risk for progression to preeclampsia with severe features within 2 weeks.

The assay results should only be used in conjunction with information available from clinical evaluations and other standard of care procedures. The test result is not to be used to replace clinical judgment.

Compliance Category

FDA

Note

This test should not be used for a woman with a multiple pregnancy (i.e., pregnancy with more than one fetus). This test should also not be used in pregnant women who received intravenous heparin within 24 hours.

Hotline History

View Hotline History

 

Hotline History

Date of Change
Test Name Change
Methodology
Performance/Reported Schedule
Specimen Requirements
Reference Interval
Interpretive Data
Note
CPT Code
Component Change
Other Interface Change
New Test
Inactive
08/19/2024
X
N/A

CPT Codes

83520 x2

Are you an ARUP Client? Click here for your pricing.

Components

Component Test Code* Component Chart Name LOINC
3018308 Preeclampsia sFlt-1/PlGF Ratio, S/P 74757-6
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.

Aliases

  • Gestational hypertension
  • Hypertensive disorders of pregnancy
  • PlGF (Placental Growth Factor)
  • Preeclampsia ratio
  • Preeclampsia risk
  • sFlt-1 (soluble fms-like tyrosine kinase 1)
  • sFlt-1/PlGF Ratio
Preeclampsia Risk Assessment (sFlt-1/PlGF Ratio)